The key paper that provides guidance about how to monitor patients who are on a second-generation (“atypical”) antipsychotic for metabolic syndrome is:
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004 Feb;65(2):267-72. PubMed PMID: 15003083.
The full text of this article is available free at this link:
http://care.diabetesjournals.org/content/27/2/596.full.pdf
Related Pages
Monitoring form for second-generation antipsychotics
FDA issues new warning about aripiprazole (impulse control problems) (Free)
Changes in rules about clozapine
Second-Generation (“Atypical”) Antipsychotics
Copyright 2015, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply